Genome-Wide Association Study and Gene Expression Analysis Identifies as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

English version České info

Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers to predict response or new drugs to target refractory cases. To understand the biological basis of response to anti-TNF therapy, we conducted a genome-wide association study (GWAS) meta-analysis of more than 2 million common variants in 2,706 RA patients from 13 different collections. Patients were treated with one of three anti-TNF medications: etanercept (n = 733), infliximab (n = 894), or adalimumab (n = 1,071). We identified a SNP (rs6427528) at the 1q23 locus that was associated with change in disease activity score (ΔDAS) in the etanercept subset of patients (P = 8×10⁻⁸), but not in the infliximab or adalimumab subsets (P>0.05). The SNP is predicted to disrupt transcription factor binding site motifs in the 3′ UTR of an immune-related gene, CD84, and the allele associated with better response to etanercept was associated with higher CD84 gene expression in peripheral blood mononuclear cells (P = 1×10⁻¹¹ in 228 non-RA patients and P = 0.004 in 132 RA patients). Consistent with the genetic findings, higher CD84 gene expression correlated with lower cross-sectional DAS (P = 0.02, n = 210) and showed a non-significant trend for better ΔDAS in a subset of RA patients with gene expression data (n = 31, etanercept-treated). A small, multi-ethnic replication showed a non-significant trend towards an association among etanercept-treated RA patients of Portuguese ancestry (n = 139, P = 0.4), but no association among patients of Japanese ancestry (n = 151, P = 0.8). Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity. These findings support a model in which CD84 genotypes and/or expression may serve as a useful biomarker for response to etanercept treatment in RA patients of European ancestry.

Vyšlo v časopise: Genome-Wide Association Study and Gene Expression Analysis Identifies as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genet 9(3): e32767. doi:10.1371/journal.pgen.1003394
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003394

Souhrn

Zdroje

1. KlareskogL, CatrinaAI, PagetS (2009) Rheumatoid arthritis. Lancet 373 : 659–672.

2. ScottDL, WolfeF, HuizingaTW (2010) Rheumatoid arthritis. Lancet 376 : 1094–1108.

3. McInnesIB, SchettG (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365 : 2205–2219.

4. AeberliD, SeitzM, JuniP, VilligerPM (2005) Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 44 : 172–175.

5. AgnholtJ, DahlerupJF, KaltoftK (2003) The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23 : 76–85.

6. CatrinaAI, TrollmoC, af KlintE, EngstromM, LampaJ, et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52 : 61–72.

7. ScallonBJ, MooreMA, TrinhH, KnightDM, GhrayebJ (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 : 251–259.

8. GudbrandsdottirS, LarsenR, SorensenLK, NielsenS, HansenMB, et al. (2004) TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 22 : 118–124.

9. PlantD, PrajapatiR, HyrichKL, MorganAW, WilsonAG, et al. (2012) Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64 : 665–670.

10. PrajapatiR, PlantD, BartonA (2011) Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 12 : 1571–1585.

11. CuiJ, SaevarsdottirS, ThomsonB, PadyukovL, van der Helm-Van MilAH, et al. (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62 : 1849–1861.

12. PlantD, BowesJ, PotterC, HyrichKL, MorganAW, et al. (2011) Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 63 : 645–653.

13. LiuC, BatliwallaF, LiW, LeeA, RoubenoffR, et al. (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 14 : 575–581.

14. PrevooML, van 't HofMA, KuperHH, van LeeuwenMA, van de PutteLB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 : 44–48.

15. van GestelAM, PrevooML, van 't HofMA, van RijswijkMH, van de PutteLB, et al. (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39 : 34–40.

16. WardLD, KellisM (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40: D930–934.

17. ErnstJ, KheradpourP, MikkelsenTS, ShoreshN, WardLD, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473 : 43–49.

18. CooperGM, StoneEA, AsimenosG, GreenED, BatzoglouS, et al. (2005) Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 15 : 901–913.

19. SolimanMM, HyrichKL, LuntM, WatsonKD, SymmonsDP, et al. (2012) Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken)

20. TangyeSG, NicholsKE, HareNJ, van de WeerdtBC (2003) Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation. J Immunol 171 : 2485–2495.

21. MartinM, RomeroX, de la FuenteMA, TovarV, ZapaterN, et al. (2001) CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol 167 : 3668–3676.

22. PadyukovL, LampaJ, HeimburgerM, ErnestamS, CederholmT, et al. (2003) Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 62 : 526–529.

23. CoenenMJ, EnevoldC, BarreraP, SchijvenaarsMM, ToonenEJ, et al. (2010) Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS ONE 5: e14326 doi:10.1371/journal.pone.0014326.

24. ToonenEJ, CoenenMJ, KievitW, FransenJ, EijsboutsAM, et al. (2008) The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 67 : 1174–1177.

25. Miceli-RichardC, CometsE, VerstuyftC, TamouzaR, LoiseauP, et al. (2008) A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 67 : 478–484.

26. CanhaoH, FaustinoA, MartinsF, FonsecaJE (2011) Reuma.pt -⁠ the rheumatic diseases portuguese register. Acta Reumatol Port 36 : 45–56.

27. OkadaY, TeraoC, IkariK, KochiY, OhmuraK, et al. (2012) Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet

28. StahlEA, RaychaudhuriS, RemmersEF, XieG, EyreS, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42 : 508–514.

29. PlengeRM, SeielstadM, PadyukovL, LeeAT, RemmersEF, et al. (2007) TRAF1-C5 as a Risk Locus for Rheumatoid Arthritis –⁠ A Genomewide Study. N Engl J Med 357 : 1199–1209.

30. PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 : 559–575.

31. PriceAL, PattersonNJ, PlengeRM, WeinblattME, ShadickNA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38 : 904–909.

32. MarchiniJ, HowieB, MyersS, McVeanG, DonnellyP (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39 : 906–913.

33. StahlEA, WegmannD, TrynkaG, Gutierrez-AchuryJ, DoR, et al. (2012) Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet

34. GauthierSA, GlanzBI, MandelM, WeinerHL (2006) A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev 5 : 532–536.

35. StegleO, PartsL, DurbinR, WinnJ (2010) A Bayesian framework to account for complex non-genetic factors in gene expression levels greatly increases power in eQTL studies. PLoS Comput Biol 6: e1000770 doi:10.1371/journal.pcbi.1000770.

36. De JagerPL, JiaX, WangJ, de BakkerPI, OttoboniL, et al. (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41 : 776–782.

37. StrangerBE, NicaAC, ForrestMS, DimasA, BirdCP, et al. (2007) Population genomics of human gene expression. Nat Genet 39 : 1217–1224.

38. ParkerA, IzmailovaES, NarangJ, BadolaS, LeT, et al. (2007) Peripheral Blood Expression of Nuclear Factor-kappaB-Regulated Genes Is Associated with Rheumatoid Arthritis Disease Activity and Responds Differentially to Anti-Tumor Necrosis Factor-alpha versus Methotrexate. J Rheumatol 34 : 1817–1822.

39. BatliwallaFM, BaechlerEC, XiaoX, LiW, BalasubramanianS, et al. (2005) Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 6 : 388–397.

40. DevlinB, RoederK, WassermanL (2001) Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 60 : 155–166.

41. de BakkerPI, FerreiraMA, JiaX, NealeBM, RaychaudhuriS, et al. (2008) Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genet 17: R122–128.